



Introduction


Submicron characterization of the physicochemical properties of dry powder inhaler (DPI) particles is critical to gain an understanding of the formulation attributes that can affect the aerosol performance of a DPI.

Optical Photothermal Infrared Spectroscopy (O-PTIR) is a pump-probe technique that utilizes photothermal expansion for infrared and Raman imaging with a spatial resolution of ~300-500 nm for the solid-state assessment of chemical composition, morphology, crystallinity, and the evaluation of co-localization of drugs and/or excipients in different aerodynamic particle size fractions.^{1,2}

Objectives


Employ O-PTIR to characterize and compare the chemical composition of aerosolized fractions and drug-excipient agglomeration behavior of particles after the dispersion from Advair Diskus 100/50 and Wixela Inhub 100/50 DPIs (Fluticasone Propionate; Salmeterol Xinafoate Inhalation Powders).

Materials and Methods




Aerosolized fractions (60 L/min) of Advair Diskus 100/50 and Wixela Inhub 100/50 were collected on calcium fluoride (CaF₂) placed at different stages of a Next Generation Impactor (NGI) followed by O-PTIR measurements using mIRage-LS (Photothermal Spectroscopy Corp.).

Results




a) O-PTIR spectra of fluticasone propionate (FP), salmeterol xinafoate (SX), and lactose (L) raw materials. Representative identification peaks are labelled for each component.


Results cont'd.



Single wavenumber chemical maps, direct current (DC) image and spectral array collected from aerosolised a) Advair Diskus 100/50 and b) Wixela Inhub 100/50 particles collected from Stage 3 of the NGI showing the distribution of FP, SX, and L.



Colocalization analysis of FP, SX, and L of aerosolised a) Advair Diskus 100/50 and b) Wixela Inhub 100/50 particles collected from Stage 3 of the NGI. Degree of colocalization is represented as a percentage (%) via the Manders Coefficient.



Scattered plots of integrated intensity vs. area of particles demonstrating the particle size distribution of FP, SX, and L across the aerosolised a) Advair Diskus 100/50 and b) Wixela Inhub 100/50 particles collected from Stage 3 of the NGI.

Results cont'd.

Colocalized components	Percentage of colocalization Weighted Average (Multiple Region of Interests) (%)		Composition of the particles	Weighted Average of spectroscopic diameter (Multiple Region of Interests) (μm) (mean ± SD)	
	Advair Diskus	Wixela Inhub		Advair Diskus	Wixela Inhub
FP/L	100 ± 0	100 ± 0	FP	2.1 ± 1.1	2.5 ± 0.7
L/FP	29 ± 20	47 ± 17	SX	1.4 ± 0.6	1.5 ± 0.4
FP/SX	100 ± 0	100 ± 0	L	2.9 ± 2.0	2.9 ± 0.6
SX/FP	66 ± 28	75 ± 18	FP/SX	1.9 ± 1.2	2.0 ± 0.5
SX/L	78 ± 28	83 ± 11	FP/L	1.9 ± 1.1	2.0 ± 0.2
L/SX	34 ± 26	51 ± 13	SX/L	1.4 ± 0.6	1.7 ± 0.3
			FP/SX/LH	2.6 ± 1.4	2.5 ± 0.6

Summary of colocalization of FP, SX, and L along with the spectroscopic diameter of individual FP, SX, L particles and colocalized multicomponent particles for Advair Diskus 100/50 and Wixela Inhub 100/50 particles across multiple regions of interest on Stage 3 of the NGI. Analysis was based on the single wavenumber chemical mapping followed by colocalization analysis. (N=>>10,000 pixels across all ROIs, each pixel size is 300 nm).

Conclusions

- Advair Diskus 100/50 had a higher percentage of lactose which was not colocalized with the active pharmaceutical ingredients (APIs) compared to Wixela Inhub 100/50 particles.
- Fluticasone propionate particles are colocalized with lactose and/or salmeterol xinafoate particles (100 %).
- Only 66-75% of salmeterol xinafoate particles are colocalized with fluticasone propionate particles.
- Both formulations contain fine lactose particles.
- O-PTIR allows the solid-state chemical analysis of the distribution of drugs and excipients within DPI formulations at a resolution of 0.5 microns which may not be possible using conventional chemical imaging techniques with a resolution of 5 microns.
- This analytical tool allows for the design and optimization of DPI formulations to achieve the desired product performance.

Acknowledgments

The research funding for this work was made possible by the U.S. Food and Drug Administration (FDA) through Contract 75F40122C00202; views expressed in this poster are from the authors only and do not necessarily reflect the FDA's official views or policies nor does any mention of trade names, commercial practices, or organization imply endorsement by the U.S. Government.

References

- Khanal et.al, *Anal Chem* 2020, 92: 8323–8332.
- Khanal et.al, *Int J Pharm* 2023, 632: 122563.